【摘要】 目的研究雌激素(ER)和雄激素(AR)受体与泌乳素腺瘤临床表现之间的相关关系,探讨泌乳素腺瘤发病机理中ER和AR表达可能存在的性别差异。方法搜集同济医院2000年12月～2001年12月期间经蝶窦手术的30例泌乳素腺瘤病例,实验分为两部分。第一部分：回顾性分析了病人性别、年龄、血浆泌乳素水平、肿瘤的大小、侵袭性、CT和MRI以及手术发现、术前使用溴隐亭情况和肿瘤复发等临床资料,第二部分：选取30例中的20例泌乳素腺瘤标本,用免疫组化技术检测了ER和AR的表达。运用卡方检测行统计学分析泌乳素腺瘤的各种临床特点和ER、AR表达间的关系。结果统计分析结果显示ER和AR的表达与泌乳素腺瘤的特征如：性别、年龄、肿瘤体积、肿瘤的侵袭性无关(P＞0.05)。结论泌乳素腺瘤的性别、年龄、肿瘤体积、肿瘤的侵袭性程度不会影响ER和AR的表达。男性泌乳素腺瘤较女性患者更具侵袭性。单纯手术治疗巨大腺瘤或血浆泌乳素＞200ng／mL的肿瘤疗效并不理想。手术后溴隐亭治疗的应用与患者的性别无关,但与手术前肿瘤的体积和泌乳素水平相关。更多还原

【Abstract】 To study the correlations between estrogen receptor (ER) and androgen receptor (AR) and the clinical presentations of prolactinoma and investigate the effect of ER and AR expression on the pathogenesis of prolactinoma in sexual difference. Methods: The clinical data of 30 patients who had undergone transsphenoidal operations in Tongji Hospital from December 2000 to December 2001 were reviewed retrospectively. The clinical information included sex, age, serum-prolactin, size, tumor invasiveness, history of use of bromocriptine and frequency of recurrence. In 20 out of the 30 patients, the ER and AR expression was detected by using immunohistochemistry method. With help of Chi-square test, the relationship between ER, AR and the clinical presentations was analyzed. Results: The statistical values revealed that there was no significant correlation between the ER and AR expression levels with the clinical presentations such as sex, age, tumor size or tumor invasiveness among the 20 patients studied (P>0.05). Conclusion: The expression of ER or AR is not influenced by the clinical data of prolactinoma such as sex, age, tumor diameter or extent of tumor invasiveness. The tumor is more aggressive in males than in females. In maroadenoma or tumor with hyperprolactineamia (>200 ng/mL) simple surgical treatment can’t successfully cure the prolactinoma. Post-operative bromocriptine therapy can’t be determined by the sex of the patients, but is greatly related to the tumor size and serum-prolactin level before operation.更多还原